Ekso Bionics Raises $5.9 Million via Convertible Preferred and Warrants in Private Placement

New updates have been reported about Ekso Bionics.

Ekso Bionics Holdings has secured approximately $5.9 million in gross proceeds through a private placement of Series B Preferred Stock and accompanying warrants, reinforcing its balance sheet for near-term operating needs. Under securities purchase agreements signed on January 20, 2026, the company will issue 5,852 shares of Series B Preferred Stock, each with a $1,000 stated value, which are convertible into a total of 711,922 common shares at $8.22 per share. The preferred shares vote with common stock on an as-converted basis, subject to ownership limitations, effectively giving new investors equity-linked economic and governance exposure while delaying common share issuance until conversion. Ekso will also issue warrants to purchase up to 355,960 common shares, exercisable at $8.22 per share, with a five-year term beginning six months after the expected January 22, 2026 closing, but only if the holder is no longer holding preferred or the conversion shares at the time of exercise, limiting concurrent dilution.

Net proceeds, after placement agent fees and offering expenses, are earmarked for working capital and general corporate purposes, indicating the raise is primarily to support ongoing operations rather than a defined acquisition or capex initiative. Structurally, the transaction introduces potential future dilution through both convertible preferred and warrants at a premium to many historical trading levels, while providing immediate liquidity to fund Ekso Bionics’ exoskeleton business across medical and industrial markets. The securities are being sold in a private, unregistered offering under Section 4(a)(2) of the Securities Act, with resale restricted absent a registration statement or applicable exemption. Management highlights standard forward-looking risks around liquidity, capital needs, and macro conditions, signaling that continued access to capital markets remains strategically important as the company pursues growth in rehabilitation robotics and industrial exoskeletons. Lake Street Capital Markets acted as exclusive placement agent on the deal.